Chardan Capital Raises PT to $80, Maintains Buy Rating on Praxis.

Chardan Capital Raises PT to $80, Maintains Buy Rating on Praxis.

Chardan Capital has recently raised its price target to $80, while maintaining a "buy" rating on Praxis Precision Medicines Inc. (PRAX), according to a research note dated July 8, 2025 [2]. This move comes amidst a positive market sentiment surrounding the company's clinical pipeline advancements, particularly in the treatment of Developmental Epileptic Encephalopathy using Relutrigine.

The research note from Chardan Capital underscores the potential of Praxis Precision Medicines' drug development programs, highlighting the success of Relutrigine in late-stage trials. This positive outlook aligns with other analysts' sentiments, with Oppenheimer recently increasing its price target to $115 and Needham & Company LLC setting a price objective of $80 [2].

Praxis Precision Medicines' stock has shown resilience and positive momentum, with the stock trading up by 6.67% on November 26, 2024, following its latest quarterly earnings report [1]. Despite missing Q3 EPS expectations, the company's drug development progress, especially in Relutrigine, has sparked investor interest.

The market's cautious optimism is reflected in the revised price targets from various analysts. While Wedbush maintains a neutral outlook, Oppenheimer and Needham & Company LLC exhibit more bullish sentiments, reflecting the potential of Praxis Precision Medicines' pipeline and strategic advancements [2].

The company's stock has a market capitalization of $1.21 billion, a PE ratio of -5.52, and a beta of 2.60, indicating a high-risk, high-reward profile [2]. This profile is typical of biotech companies, which often experience significant volatility due to the potential for breakthrough treatments.

In conclusion, Chardan Capital's revised price target and "buy" rating on Praxis Precision Medicines reflect the positive market sentiment surrounding the company's clinical pipeline and strategic advancements. Investors should closely monitor the company's drug development progress and regulatory filings for further insights into its potential.

References:
[1] https://www.timothysykes.com/news/praxis-precision-medicines-inc-prax-news-2024_11_26/
[2] https://www.marketbeat.com/instant-alerts/praxis-precision-medicines-inc-nasdaqprax-receives-consensus-rating-of-moderate-buy-from-analysts-2025-07-23/